First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Béla Ózsvári; Federica Sotgia; Michael P. Lisanti

doi:doi:10.18632/aging.103336

← Back

Research Paper Volume 12, Issue 11 pp 10162—10179

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Figure 13. A large mito-ribosome gene signature predicts distant metastasis and tumor recurrence in ER(-)/basal breast cancer patients. In ER(-)/basal breast cancer, a 6-gene mito-ribosome signature was also able to effectively predict distant metastasis in N=145 patients (HR=2.95; P=0.0018) and tumor recurrence in N=360 patients (HR=2.19; P=1.9e-06). See also Supplementary Table 8.